Literature DB >> 31152400

Fluorogenic Assays for the Defatty-Acylase Activity of Sirtuins.

Jun Young Hong1, Ji Cao1, Hening Lin2.   

Abstract

Sirtuins are type III histone deacetylases (HDAC) that uses nicotinamide adenine dinucleotide as cosubstrate. Dysfunction of sirtuins is implicated in wide varieties of human diseases. As such, there has been increased interest in the development of small molecule to modulate sirtuin activities. Besides deacetylase activity, recent studies suggest SIRT1, 2, 3, and 6 efficiently remove fatty acyl groups on lysine. In vitro sirtuin enzymatic activity assays established so far are mainly based on the deacetylation activity. Here, we describe a fluorogenic assay for monitoring defatty-acylase activity of SIRT1, 2, 3 and 6 using peptide substrates. This assay can be utilized to evaluate sirtuin modulators in high-throughput manners.

Entities:  

Keywords:  Defatty-acylase; Enzymatic assay; Fluorogenic assay; SIRT1; SIRT2; SIRT3; SIRT6

Mesh:

Substances:

Year:  2019        PMID: 31152400      PMCID: PMC6893880          DOI: 10.1007/978-1-4939-9532-5_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  14 in total

Review 1.  Franklin H. Epstein Lecture: Sirtuins, aging, and medicine.

Authors:  Leonard Guarente
Journal:  N Engl J Med       Date:  2011-06-09       Impact factor: 91.245

Review 2.  NAD+ and sirtuins in aging and disease.

Authors:  Shin-ichiro Imai; Leonard Guarente
Journal:  Trends Cell Biol       Date:  2014-04-29       Impact factor: 20.808

3.  Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins.

Authors:  Jessica L Feldman; Josue Baeza; John M Denu
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

4.  A fluorogenic assay for screening Sirt6 modulators.

Authors:  Jing Hu; Bin He; Shiva Bhargava; Hening Lin
Journal:  Org Biomol Chem       Date:  2013-08-28       Impact factor: 3.876

5.  Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme.

Authors:  José L Avalos; Katherine M Bever; Cynthia Wolberger
Journal:  Mol Cell       Date:  2005-03-18       Impact factor: 17.970

Review 6.  Sirtuin inhibitors as anticancer agents.

Authors:  Jing Hu; Hui Jing; Hening Lin
Journal:  Future Med Chem       Date:  2014-05       Impact factor: 3.808

7.  Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

Authors:  Tiago Fleming Outeiro; Eirene Kontopoulos; Stephen M Altmann; Irina Kufareva; Katherine E Strathearn; Allison M Amore; Catherine B Volk; Michele M Maxwell; Jean-Christophe Rochet; Pamela J McLean; Anne B Young; Ruben Abagyan; Mel B Feany; Bradley T Hyman; Aleksey G Kazantsev
Journal:  Science       Date:  2007-06-21       Impact factor: 47.728

8.  Efficient demyristoylase activity of SIRT2 revealed by kinetic and structural studies.

Authors:  Yan-Bin Teng; Hui Jing; Pornpun Aramsangtienchai; Bin He; Saba Khan; Jing Hu; Hening Lin; Quan Hao
Journal:  Sci Rep       Date:  2015-02-23       Impact factor: 4.379

9.  SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation.

Authors:  Xiaoyu Zhang; Nicole A Spiegelman; Ornella D Nelson; Hui Jing; Hening Lin
Journal:  Elife       Date:  2017-04-13       Impact factor: 8.140

10.  SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a.

Authors:  Hui Jing; Xiaoyu Zhang; Stephanie A Wisner; Xiao Chen; Nicole A Spiegelman; Maurine E Linder; Hening Lin
Journal:  Elife       Date:  2017-12-14       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.